tbuckley/cabot-search huggingface dataset:
Transitioning From SIRS to Phoenix With the Updated Pediatric Sepsis Criteria—The Difficult Task of Simplifying the Complex
Authors: Roberto Jabornisky, Nathan Kuppermann, Sebastián González-Dambrauskas
Journal: JAMA (2024)

L. Nelson Sanchez-Pinto, MD, MBI; Tellen D. Bennett, MD, MS; Peter E. DeWitt, PhD; Seth Russell, MS; Margaret N. Rebull, MA; Blake Martin, MD; Samuel Akech, MBChB, MMED; David J. Albers, PhD; Elizabeth R. Alpern, MD, MSCE; Fran Balamuth, MD, PhD, MSCE; Melania Bembea, MD, MPH, PhD; Mohammod Jobayer Chisti, MBBS, MMed, PhD; Idris Evans, MD, MSc; Christopher M. Horvat, MD, MHA; Juan Camilo Jaramillo-Bustamante, MD; Niranjan Kissoon, MD; Kusum Menon, MD, MSc; Halden F. Scott, MD, MSCS; Scott L. Weiss, MD; Matthew O. Wiens, PharmD, PhD; Jerry J. Zimmerman, MD, PhD; Andrew C. Argent, MD, MBBCh, MMed; Lauren R. Sorce, PhD, RN, CPNP-AC/PC; Luregn J. Schlapbach, MD, PhD; R. Scott Watson, MD, MPH; Society of Critical Care Medicine Pediatric Sepsis Definition Task Force; Paolo Biban, MD; Enitan Carrol, MD, MBChB; Kathleen Chiotos, MD; Claudio Flauzino De Oliveira, MD, PhD; Mark W. Hall, MD; David Inwald, MB, MB BChir, PhD; Paul Ishimine, MD; Michael Levin, MD, PhD; Rakesh Lodha, MD; Simon Nadel, MBBS; Satoshi Nakagawa, MD; Mark J. Peters, PhD; Adrienne G. Randolph, MD, MS; Suchitra Ranjit, MD; Daniela Carla Souza, MD; Pierre Tissieres, MD, DSc; James L. Wynn, MD
Context and Implications of the New Pediatric Sepsis Criteria
Authors: Erin F. Carlton, Mallory A. Perry-Eaddy, Hallie C. Prescott
Journal: JAMA (2024)

L. Nelson Sanchez-Pinto, MD, MBI; Tellen D. Bennett, MD, MS; Peter E. DeWitt, PhD; Seth Russell, MS; Margaret N. Rebull, MA; Blake Martin, MD; Samuel Akech, MBChB, MMED; David J. Albers, PhD; Elizabeth R. Alpern, MD, MSCE; Fran Balamuth, MD, PhD, MSCE; Melania Bembea, MD, MPH, PhD; Mohammod Jobayer Chisti, MBBS, MMed, PhD; Idris Evans, MD, MSc; Christopher M. Horvat, MD, MHA; Juan Camilo Jaramillo-Bustamante, MD; Niranjan Kissoon, MD; Kusum Menon, MD, MSc; Halden F. Scott, MD, MSCS; Scott L. Weiss, MD; Matthew O. Wiens, PharmD, PhD; Jerry J. Zimmerman, MD, PhD; Andrew C. Argent, MD, MBBCh, MMed; Lauren R. Sorce, PhD, RN, CPNP-AC/PC; Luregn J. Schlapbach, MD, PhD; R. Scott Watson, MD, MPH; Society of Critical Care Medicine Pediatric Sepsis Definition Task Force; Paolo Biban, MD; Enitan Carrol, MD, MBChB; Kathleen Chiotos, MD; Claudio Flauzino De Oliveira, MD, PhD; Mark W. Hall, MD; David Inwald, MB, MB BChir, PhD; Paul Ishimine, MD; Michael Levin, MD, PhD; Rakesh Lodha, MD; Simon Nadel, MBBS; Satoshi Nakagawa, MD; Mark J. Peters, PhD; Adrienne G. Randolph, MD, MS; Suchitra Ranjit, MD; Daniela Carla Souza, MD; Pierre Tissieres, MD, DSc; James L. Wynn, MD
Gint4.T-siHDGF chimera-capped mesoporous silica nanoparticles encapsulating temozolomide for synergistic glioblastoma therapy
Authors: Huaijun Fei, Yang Jin, Nan Jiang, Yuhan Zhou, Ningcheng Wei, Yifan Liu, Jiayi Miao, Liying Zhang, Rui Li, Aixia Zhang, Shuhu Du
Journal: Biomaterials (2024)
Glycemic Trends in Patients with Thyroid Eye Disease Treated with Teprotumumab in 3 Clinical Trials
Authors: Terry J. Smith, Dustin Cavida, Kate Hsu, Sun Kim, Qianhong Fu, Giuseppe Barbesino, Sara Tullis Wester, Robert J. Holt, Rajib K. Bhattacharya
Journal: Ophthalmology (2024)

Objective Assess incidence, severity, and outcomes of serum glucose excursions in patients with thyroid eye disease who received the insulin-like growth factor-1 receptor inhibitor, teprotumumab, during pivotal clinical trials. Design Analysis of pooled glycemic data and longitudinal trends. Subjects phase 2 and phase 3 (OPTIC) pooled analysis: 170 patients (84 teprotumumab, 86 placebo); OPTIC-X: 51 patients from OPTIC. Methods Teprotumumab administered as 8 intravenous infusions over 21 weeks. In the phase 2 trial, serum glucose was measured at weeks 1, 4, 15, and 21, with fasting blood collections weeks 1 and 4. In OPTIC and OPTIC-X, serum glucose was measured at each study visit, with fasting draws weeks 1 and 4 (non-diabetic patients) or all visits (diabetic patients). In all studies, hemoglobin A1c (HbA1c) was measured at baseline, 12, and 24 weeks plus weeks 36 and 48 of OPTIC-X. Main Outcome Measures Serum glucose and HbA1c over time. Results In the pooled analysis, 9 hyperglycemic episodes were reported in 8 teprotumumab patients; mean HbA1c in teprotumumab patients increased 0.22% from baseline to week 24 (to 5.8%, range 5.0%–7.9%) versus 0.04% in placebo patients (to 5.6%, range 4.6%–8.1%). At study end, 78% of teprotumumab and 87% of placebo patients were normoglycemic. Normoglycemia was maintained from baseline to week 24 in 84% (57/68) of teprotumumab and 93% (64/69) of placebo patients. Of prediabetic patients, 43% (3/7) remained prediabetic in both groups and 29% (2/7) of teprotumumab and 14% (1/7) of placebo patients were diabetic at week 24. OPTIC-X showed a trend toward increased fasting glucose and HbA1c during teprotumumab retreatment and initial therapy (placebo patients from OPTIC). Fasting glucose commonly rose following the first 2-3 infusions and stabilized over subsequent infusions. Most hyperglycemic incidents occurred in patients with baseline prediabetes or diabetes and were controlled with medication. There was no evidence of progression or increased incidence of hyperglycemia with subsequent doses. Conclusions Serious glycemic excursions are uncommon in patients who are normoglycemic before teprotumumab therapy. Patients with controlled diabetes or impaired glucose tolerance can be treated safely if baseline screening, regular monitoring of glycemic control, and treatment of hyperglycemia are ensured.
Ursodeoxycholic Acid‐Decorated Zwitterionic Nanoparticles for Orally Liver‐Targeted Close‐Looped Insulin Delivery
Authors: Yuhong Ma, Wei Wang, Caihua Li, Fuwei Han, Mujiao He, Yinan Zhong, Dechun Huang, Wei Chen, Hongliang Qian
Journal: Advanced Healthcare Materials (2024)

Abstract Oral insulin therapies targeting the liver and further simulating close‐looped secretion face significant challenges due to multiple trans‐epithelial barriers. Herein, ursodeoxycholic acid (UDCA)‐decorated zwitterionic nanoparticles (NPs) (UC‐CMs@ins) are designed to overcome these barriers, target the liver, and respond to glycemia, thereby achieving oral one‐time‐per‐day therapy. UC‐CMs@ins show excellent mucus permeability through the introduction of zwitterion (carboxy betaine, CB). Furthermore, UC‐CMs@ins possess superior cellular internalization via proton‐assisted amino acid transporter 1 (PAT1, CB‐receptor) and apical sodium‐dependent bile acid transporter (ASBT, UDCA‐receptor) pathways. Moreover, UC‐CMs@ins exhibit excellent endolysosomal escape ability and improve the basolateral release of insulin into the bloodstream via the ileal bile acid‐binding protein and the heteromeric organic solute transporter (OSTα‐ OSTβ) routes compared with non‐UDCA‐decorated C‐CMs@ins. Therefore, CB and UDCA jointly overcome mucus and intestinal barriers. Additionally, UC‐CMs@ins prevent insulin degradation in the gastrointestinal tract for crosslinked structure, improve insulin accumulation in the liver for UDCA introduction, and effectively regulate glycemia for “closed‐loop” glucose control. Surprisingly, oral ingestion of UC‐CMs@ins shows a superior effect on glycemia (≈22 h, normoglycemia) and improves postprandial glycemic levels in diabetic mice, illustrating the enormous potential of the prepared NPs as a platform for oral insulin administration in diabetes treatment.
Glutathione Depletion‐Induced Versatile Nanomedicine for Potentiating the Ferroptosis to Overcome Solid Tumor Radioresistance and Enhance Immunotherapy
Authors: Huijuan Song, Hao Sun, Ningning He, Chang Xu, Liqing Du, Kaihua Ji, Jinhan Wang, Manman Zhang, Yeqing Gu, Yan Wang, Qiang Liu
Journal: Advanced Healthcare Materials (2024)

Abstract A high level of reduced glutathione is a major factor contributing to the radioresistance observed in solid tumors. To address this radioresistance associated with glutathione, a cinnamaldehyde (CA) polymer prodrug, referred to as PDPCA, is fabricated. This prodrug is created by synthesizing a pendent CA prodrug with acetal linkages in a hydrophobic block, forming a self‐assembled into a core–shell nanoparticle in aqueous media. Additionally, it encapsulates all‐ trans retinoic acid (ATRA) for synchronous delivery, resulting in PDPCA@ATRA. The PDPCA@ATRA nanoparticles accumulate reactive oxygen species through both endogenous and exogenous pathways, enhancing ferroptosis by depleting glutathione. This approach demonstrates efficacy in overcoming tumor radioresistance in vivo and in vitro, promoting the ferroptosis, and enhancing the cytotoxic T lymphocyte (CTL) response for lung tumors to anti‐PD‐1 (αPD‐1) immunotherapy. Furthermore, this study reveals that PDPCA@ATRA nanoparticles promote ferroptosis through the NRF2‐GPX4 signaling pathway, suggesting the potential for further investigation into the combination of radiotherapy and αPD‐1 immune checkpoint inhibitors in cancer treatment.
One‐Step Synthesis of Hydrogel Adhesive with Acid‐Responsive Tannin Release for Diabetic Oral Mucosa Defects Healing
Authors: Kaize Su, Jinxuan Li, Xiaoxian Wu, Duanyu Deng, Han Gu, Ying Sun, Xu Wang, Wenhuan Huang, Yan Wang, Xiangcun Shang, Cuiyu Xue, Lihua Liang, Xiaofang Li, Dongli Li, Song Ang, Kun Zhang, Panpan Wu, Keke Wu
Journal: Advanced Healthcare Materials (2024)

Abstract The complex preparation, weak wet tissue adhesion, and limited biological activity of traditional oral wound dressings usually impede their efficient treatment and healing for diabetic oral mucosal defects. To overcome these problems, a novel hydrogel adhesive (named CFT hydrogel) is rapidly constructed using a one‐step method based on dual‐dynamic covalent cross‐linking. Compared with the commercial oral patches, the CFT hydrogel shows superior in vivo (rat tongue) wet tissue adhesion performance. Additionally, the CFT hydrogel exhibits unique acid‐responsive properties, thereby facilitating the release of bioactive molecule tannic acid in the acidic diabetic wound microenvironment. And a series of in vitro experiments substantiate the favorable biocompatibility and bioactivity properties (including antibacterial, antioxidative, anti‐inflammatory, and angiogenetic effects) exhibited by CFT hydrogel. Moreover, in vivo experiments conducted on a diabetic rat model with oral mucosal defects demonstrate that the CFT hydrogel exhibits significant efficacy in protecting against mucosal wounds, alleviating inflammatory reactions, thereby facilitating the wound‐healing process. Taken together, this study provides a promising and comprehensive therapeutic option with great potential for the clinical management of oral mucosa defects in diabetic patients.
A nanoenzyme-modified hydrogel targets macrophage reprogramming-angiogenesis crosstalk to boost diabetic wound repair
Authors: Shan He, Zhenhao Li, Lu Wang, Nannan Yao, Huangding Wen, Huageng Yuan, Jiatao Zhang, Zhiqing Li, Chuanan Shen
Journal: Bioactive Materials (2024)

Diabetic wounds has a gradually increasing incidence and morbidity. Excessive inflammation due to immune imbalance leads to delayed wound healing. Here, we reveal the interconnection between activation of the NLRP3 inflammatory pathway in endotheliocyte and polarization of macrophages via the cGAS-STING pathway in the oxidative microenvironment. To enhance the immune-regulation based on repairing mitochondrial oxidative damage, a zeolitic imidazolate framework-8 coated with cerium dioxide that carries Rhoassociated protein kinase inhibition Y-27632 (CeO2–Y@ZIF-8) is developed. It is encapsulated in a photocross-linkable hydrogel (GelMA) with cationic quaternary ammonium salt groups modified to endow the antibacterial properties (CeO2–Y@ZIF-8@Gel). CeO2 with superoxide dismutase and catalase activities can remove excess reactive oxygen species to limit mitochondrial damage and Y-27632 can repair damaged mitochondrial DNA, thus improving the proliferation of endotheliocyte. After endotheliocyte uptakes CeO2–Y@ZIF-8 NPs to degrade peroxides into water and oxygen in cells and mitochondria, NLRP3 inflammatory pathway is inhibited and the leakage of oxidatively damaged mitochondrial DNA (Ox-mtDNA, a damage-associated molecular pattern) through mPTP decreases. Futhermore, as the cGAS-STING pathway activated by Ox-mtDNA down-regulated, the M2 phenotype polarization and anti-inflammatory factors increase. Collectively, CeO2–Y@ZIF-8@Gel, through remodulating the crosstalk between macrophage reprogramming and angiogenesis to alleviate inflammation in the microenvironment and accelerates wound healing.
Donor Electrocardiogram Associations With Cardiac Dysfunction, Heart Transplant Use, and Survival
Authors: Natalie Tapaskar, Brian Wayda, Darren Malinoski, Helen Luikart, Tahnee Groat, John Nguyen, John Belcher, Javier Nieto, Nikole Neidlinger, Ahmad Salehi, P.J. Geraghty, Bruce Nicely, Martin Jendrisak, Thomas Pearson, R. Patrick Wood, Shiqi Zhang, Yingjie Weng, Jonathan Zaroff, Kiran K. Khush
Journal: JACC Heart Failure (2024)
Engineering Improved CAR T Cell Products with A Multi‐Cytokine Particle Platform for Hematologic and Solid Tumors
Authors: Heather K. Lin, Biaggio Uricoli, Ruby Freeman, AKM Nawshad Hossian, Zhulin He, Ji Young L. Anderson, Milla Neffling, Jonathan M. Legier, Dejah A. Blake, Deon B. Doxie, Remya Nair, Jean L. Koff, Kavita M. Dhodapkar, Mala Shanmugam, Erik C. Dreaden, Sarwish Rafiq
Journal: Advanced Healthcare Materials (2024)

Abstract Despite the remarkable clinical efficacy of chimeric antigen receptor (CAR) T cells in hematological malignancies, only a subset of patients achieves a durable complete response (dCR). DCR has been correlated with CAR T cell products enriched with T cells memory phenotypes. Therefore, reagents that consistently promote memory phenotypes during the manufacturing of CAR T cells have the potential to significantly improve clinical outcomes. A novel modular multi‐cytokine particle (MCP) platform is developed that combines the signals necessary for activation, costimulation, and cytokine support into a single “all‐in‐one” stimulation reagent for CAR T cell manufacturing. This platform allows for the assembly and screening of compositionally diverse MCP libraries to identify formulations tailored to promote specific phenotypes with a high degree of flexibility. The approach is leveraged to identify unique MCP formulations that manufacture CAR T cell products from diffuse large B cell patients with increased proportions of memory‐like phenotypes MCP‐manufactured CAR T cells demonstrate superior anti‐tumor efficacy in mouse models of lymphoma and ovarian cancer through enhanced persistence. These findings serve as a proof‐of‐principle of the powerful utility of the MCP platform to identify “all‐in‐one” stimulation reagents that can improve the effectiveness of cell therapy products through optimal manufacturing.
Effectiveness of one dose of killed oral cholera vaccine in an endemic community in the Democratic Republic of the Congo: a matched case-control study
Authors: Espoir Bwenge Malembaka, Patrick Musole Bugeme, Chloe Hutchins, Hanmeng Xu, Juan Dent Hulse, Maya N Demby, Karin Gallandat, Jaime Mufitini Saidi, Baron Bashige Rumedeka, Moïse Itongwa, Esperance Tshiwedi-Tsilabia, Faida Kitoga, Tavia Bodisa-Matamu, Hugo Kavunga-Membo, Justin Bengehya, Jean-Claude Kulondwa, Amanda K Debes, Nagède Taty, Elizabeth C Lee, Octavie Lunguya, Justin Lessler, Daniel T Leung, Oliver Cumming, Placide Welo Okitayemba, Daniel Mukadi-Bamuleka, Jackie Knee, Andrew S Azman
Journal: The Lancet Infectious Diseases (2024)

BackgroundA global shortage of cholera vaccines has increased the use of single-dose regimens, rather than the standard two-dose regimen. There is sparse evidence on single-dose protection, particularly in children. In 2020, a mass vaccination campaign was conducted in Uvira, an endemic urban setting in eastern Democratic Republic of the Congo, resulting in largely single-dose coverage. We examined the effectiveness of a single-dose of the oral cholera vaccine Euvichol-Plus in this high-burden setting.MethodsIn this matched case-control study, we recruited individuals with medically attended confirmed cholera in the two cholera treatment facilities in the city of Uvira. The control group consisted of age-matched, sex-matched, and neighbourhood-matched community individuals. We recruited across two distinct periods: Oct 14, 2021, to March 10, 2022 (12–17 months after vaccination), and Nov 21, 2022, to Oct 18, 2023 (24–36 months after vaccination). Study staff administered structured questionnaires to all participants to capture demographics, household conditions, potential confounding variables, and vaccination status. The odds of vaccination for the case and control groups were contrasted in conditional logistic regression models to estimate unadjusted and adjusted vaccine effectiveness.FindingsWe enrolled 658 individuals with confirmed cholera and 2274 matched individuals for the control group. 99 (15·1%) individuals in the case group were younger than 5 years at the time of vaccination. The adjusted single-dose vaccine effectiveness was 52·7% (95% CI 31·4 to 67·4) 12–17 months after vaccination and 44·7% (24·8 to 59·4) 24–36 months after vaccination. Although protection in the first 12–17 months after vaccination was similar for children aged 1–4 years and older individuals, the estimate of protection in children aged 1–4 years appeared to wane during the third year after vaccination (adjusted vaccine effectiveness 32·9%, 95% CI –30·7 to 65·5), with CIs spanning the null.InterpretationA single dose of Euvichol-Plus provided substantial protection against medically attended cholera for at least 36 months after vaccination in this cholera-endemic setting. Although the evidence provides support for similar levels of protection in young children and others in the short term, protection among children younger than 5 years might wane significantly during the third year after vaccination.FundingWellcome Trust and Gavi, the Vaccine Alliance.
Material‐Intrinsic NIR‐Fluorescence Enables Image‐Guided Surgery for Ceramic Fracture Removal
Authors: Robert Nißler, Elena Totter, Sebastian G. Walter, Justus T. Metternich, Oscar Cipolato, Dimitri Nowack, Alexander Gogos, Inge K. Herrmann
Journal: Advanced Healthcare Materials (2024)

Hip arthroplasty effectively treats advanced osteoarthritis and is therefore entitled as "operation of the 20th century." With demographic shifts, the USA alone is projected to perform up to 850 000 arthroplasties annually by 2030. Many implants now feature a ceramic head, valued for strength and wear resistance. Nonetheless, a fraction, up to 0.03% may fracture during their lifespan, demanding complex removal procedures. To address this, a radiation-free, fluorescence-based image-guided surgical technique is presented. The method uses the inherent fluorescence of ceramic implant materials, demonstrated through chemical and optical analysis of prevalent implant types. Specifically, Biolox delta implants exhibited strong fluorescence around 700 nm with a 74% photoluminescence quantum yield. Emission tails are identified extending into the near-infrared (NIR-I) biological transparency range, forming a vital prerequisite for the label-free visualization of fragments. This ruby-like fluorescence could be attributed to Cr within the zirconia-toughened alumina matrix, enabling the detection of even deep-seated millimeter-sized fragments via camera-assisted techniques. Additionally, fluorescence microscopy allowed detection of µm-sized ceramic particles, enabling debris visualization in synovial fluid as well as histological samples. This label-free optical imaging approach employs readily accessible equipment and can seamlessly transition to clinical settings without significant regulatory barriers, thereby enhancing the safety, efficiency, and minimally invasive nature of fractured ceramic implant removal procedures.
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial
Authors: Andrew Blauvelt, Zoe D. Draelos, Linda Stein Gold, Javier Alonso-Llamazares, Neal Bhatia, Janet DuBois, Seth B. Forman, Melinda Gooderham, Lawrence Green, Scott T. Guenthner, Adelaide A. Hebert, Edward Lain, Angela Y. Moore, Kim A. Papp, Matthew Zirwas, Saori Kato, Scott Snyder, David Krupa, Patrick Burnett, David R. Berk, David H. Chu
Journal: Journal of the American Academy of Dermatology (2024)

Background The topical phosphodiesterase 4 inhibitor roflumilast has been studied in several dermatologic conditions. Objective Roflumilast foam 0.3% is being investigated as a topical treatment for seborrheic dermatitis (SD). Methods In this phase 3, double-blinded trial, patients with SD were randomly assigned (2:1 ratio) to once-daily roflumilast foam 0.3% or vehicle foam for 8 weeks. The primary efficacy outcome was Investigator Global Assessment (IGA) Success at week 8, defined as IGA of 0 (Clear) or 1 (Almost Clear) plus ≥2-point improvement from baseline. Safety was also assessed. Results 79.5% of roflumilast-treated and 58.0% of vehicle-treated patients met the primary endpoint (P < .001); statistically significant differences in IGA Success also favored roflumilast at week 2 (roflumilast: 43.0%; vehicle: 25.7%; P < .001) and week 4 (roflumilast: 73.1%; vehicle: 47.1%; P < .001). Roflumilast was well-tolerated with a low rate of treatment-emergent adverse events. Limitations Study limitations include the 8-week treatment period for this chronic condition. Conclusions Once-daily roflumilast foam was superior to vehicle in leading to IGA of Clear or Almost Clear plus ≥2-point improvement from baseline at 8 weeks in patients with SD. Longer trials are needed to determine durability and safety of roflumilast foam in SD.
Ixekizumab-induced urticaria is associated with the short duration of remission in psoriasis by activation of mast cells
Authors: Li Zhang, Xia Li, Xintian Xu, Yunchen Le, Han Cao, Jiayi Zhang, Feng Xue, Mengyan Hu, Yuhan Xia, Meng Pan, Lihong Chen, Jie Zheng
Journal: Journal of the American Academy of Dermatology (2024)
Excision margins for melanoma in situ on the head and neck—A single-center 10-year retrospective review of treatment with Mohs micrographic surgery
Authors: Jesalyn A. Tate, Andrew Matsumoto, Charlotte Greif, Jorena Lim, Rajiv I. Nijhawan, Divya Srivastava
Journal: Journal of the American Academy of Dermatology (2024)
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
Authors: Jeffrey S Weber, Matteo S Carlino, Adnan Khattak, Tarek Meniawy, George Ansstas, Matthew H Taylor, Kevin B Kim, Meredith McKean, Georgina V Long, Ryan J Sullivan, Mark Faries, Thuy T Tran, C Lance Cowey, Andrew Pecora, Montaser Shaheen, Jennifer Segar, Theresa Medina, Victoria Atkinson, Geoffrey T Gibney, Jason J Luke, Sajeve Thomas, Elizabeth I Buchbinder, Jane A Healy, Mo Huang, Manju Morrissey, Igor Feldman, Vasudha Sehgal, Celine Robert-Tissot, Peijie Hou, Lili Zhu, Michelle Brown, Praveen Aanur, Robert S Meehan, Tal Zaks
Journal: The Lancet (2024)
The Tokyo 2020 and Beijing 2022 Olympic Games held during the COVID-19 pandemic: planning, outcomes, and lessons learnt
Authors: Brian McCloskey, Tomoya Saito, Satoshi Shimada, Chiaki Ikenoue, Tina Endericks, Lucia Mullen, Pau Mota, Chirag K Kumar, Ramanan Laxminarayan, Richard Budgett, David Heymann, Alimuddin Zumla
Journal: The Lancet (2024)